title: Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.
abstract: Stable gastric pentadecapeptide BPC 157 is an anti-ulcer peptidergic agent, safe in inflammatory bowel disease clinical trials (GEPPPGKPADDAGLV, M.W. 1419, PL 14736) and wound healing, stable in human gastric juice and has no reported toxicity. We focused on BPC 157 as a therapy in peridontitis, esophagus, stomach, duodenum, intestine, liver and pancreas lesions. Particularly, it has a prominent effect on alcohol-lesions (i.e., acute, chronic) and NSAIDs-lesions (interestingly, BPC 157 both prevents and reverses adjuvant arthritis). In rat esophagitis and failed function of both lower esophageal sphincter (LES) and pyloric sphincters (PS), BPC 157 increased pressure in both sphincters till normal and reduced esophagitis. However, in healthy rats, it may decrease (PS) or increase (LES) the pressure in sphincters. It has strong angiogenic potential, it acts protectively on endothelium, prevents and reverses thrombus formation after abdominal aorta anastomosis, affects many central disturbances (i.e., dopamine and 5-HT system), the NO-system (either L-arginine and L-NAME effects), endothelin, acts as a free radical scavenger (counteracting CCl4-, paracetamol-, diclofenac-injuries) and exhibits neuroprotective properties. BPC 157 successfully heals the intestinal anastomosis, gastrocutaneous, duodenocutaneous and colocutaneous fistulas in rats, as well as interacting with the NO-system. Interestingly, the fistula closure was achieved even when the BPC 157 therapy was postponed for one month. In short-bowel syndrome escalating throughout 4 weeks, the constant weight gain above preoperative values started immediately with peroral and parental BPC 157 therapy and the villus height, crypth depth and muscle thickness (inner (circular) muscular layer) additionally increased. Thus, BPC 157 may improve gastrointestinal tract therapy.
authors.affiliation: Department of Pharmacology and Pathology Medical Faculty University of Zagreb, Zagreb, Croatia. sikiric@mef.hr
authors.forename: Predrag
authors.initials: P
authors.lastname: Sikiric
authors.forename: Sven
authors.initials: S
authors.lastname: Seiwerth
authors.forename: Rudolf
authors.initials: R
authors.lastname: Rucman
authors.forename: Branko
authors.initials: B
authors.lastname: Turkovic
authors.forename: Dinko Stancic
authors.initials: DS
authors.lastname: Rokotov
authors.forename: Luka
authors.initials: L
authors.lastname: Brcic
authors.forename: Marko
authors.initials: M
authors.lastname: Sever
authors.forename: Robert
authors.initials: R
authors.lastname: Klicek
authors.forename: Bozo
authors.initials: B
authors.lastname: Radic
authors.forename: Domagoj
authors.initials: D
authors.lastname: Drmic
authors.forename: Spomenko
authors.initials: S
authors.lastname: Ilic
authors.forename: Danijela
authors.initials: D
authors.lastname: Kolenc
authors.forename: Hrvoje
authors.initials: H
authors.lastname: Vrcic
authors.forename: Bozidar
authors.initials: B
authors.lastname: Sebecic
mesh_terms: D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000188:drug therapy*; D006801:Humans; D010446:Peptide Fragments / Q000627:therapeutic use*; D011506:Proteins / Q000627:therapeutic use*; D051381:Rats
chemical_list: D000897:Anti-Ulcer Agents; D010446:Peptide Fragments; D011506:Proteins; C083833:BPC 157